Press Releases

Date Title and Summary  
Toggle Summary Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , March 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 78,400 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of
Toggle Summary Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events
Conference Call Scheduled for 4:30 p.m. ET today MENLO PARK, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and full year ended December 31, 2018 and recent events. As of year-end 2018, the Company had
Toggle Summary Geron to Announce Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
MENLO PARK, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, March 7, 2019 via press release, which will be available on the Company’s website
Toggle Summary Geron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer
Aleksandra Rizo , M.D., Ph.D., former clinical lead for the imetelstat program at Janssen, joins Geron as Chief Medical Officer Additional office to be opened in New Jersey to support expansion of clinical development team Preliminary operating expense guidance for 2019 provided MENLO PARK, Calif.
Toggle Summary Geron Appoints Vice President, Pharmacovigilance and Drug Safety
MENLO PARK, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk
Toggle Summary Geron Announces New Board Leadership Structure
CEO John A. Scarlett Appointed Chairman Karin Eastham Appointed Lead Independent Director MENLO PARK, Calif. , Dec. 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced changes to the leadership structure of the Company’s Board of Directors.
Toggle Summary Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that results from IMbark, a Phase 2 clinical trial of
Toggle Summary Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
Data Support Initiation of Part 2, the Phase 3 portion of IMerge MENLO PARK, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial of imetelstat in lower risk
Toggle Summary Geron to Host Analyst and Investor Event on December 10, 2018
MENLO PARK, Calif. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y. , on Monday, December 10, 2018 . Management will be joined by clinical investigators from both IMerge and IMbark
Toggle Summary Geron to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present a company overview at the following investor conferences: Stifel 2018 Healthcare Conference in New